Paper28244635
Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
de Boer SA and 8 others. Diabetes Obes Metab, 2017. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). Papers, record 28244635. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28244635
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Atherosclerosis | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Diabetic Angiopathies | Major topic |
| Dipeptidyl-Peptidase IV Inhibitors | Major topic |
| Hyperglycemia | Major topic |
| Linagliptin | Major topic |
| Vascular Stiffness | Major topic |
| Aorta | |
| Biomarkers | |
| Blood Pressure | |
| Double-Blind Method | |
| Female | |
| Follow-Up Studies | |
| Glycated Hemoglobin | |
| Humans | |
| Hypertension | |
| Hypertriglyceridemia | |
| Hypoglycemia | |
| Male | |
| Middle Aged | |
| Pulse Wave Analysis | |
| Severity of Illness Index |
Source PubMed
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42454434 | Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42454434 | PubMed |
| 42453632 | Large-Scale Protein Assay Identifies Novel Protein Biomarkers Associated With Arterial Stiffness and Vascular Calcification Measures. | Int J Hypertens | 2026 | https://conductscience.org/library/papers/42453632 | PubMed |
| 41639755 | A cross-sectional study: carotid artery stiffness in individuals with varying cardiovascular disease risk using shear wave elasticity. | BMC Cardiovasc Disord | 2026 | https://conductscience.org/library/papers/41639755 | PubMed |
| 41280329 | Role of obesity in chronic kidney disease progression. | Curr Res Physiol | 2025 | https://conductscience.org/library/papers/41280329 | PubMed |
| 41204172 | EVATRAN (The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients): study protocol for a cross-over randomized controlled trial. | Trials | 2025 | https://conductscience.org/library/papers/41204172 | PubMed |
| 40244362 | The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40244362 | PubMed |
| 40149869 | Inhibition of DPP-4 Attenuates Endotoxemia-Induced NLRC4 Inflammasome and Inflammation in Visceral Adipose Tissue of Mice Fed a High-Fat Diet. | Biomolecules | 2025 | https://conductscience.org/library/papers/40149869 | PubMed |
| 38981645 | Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration. | BMJ | 2024 | https://conductscience.org/library/papers/38981645 | PubMed |
| 37493797 | Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes. | Eur J Clin Pharmacol | 2023 | https://conductscience.org/library/papers/37493797 | PubMed |
| 37175496 | An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175496 | PubMed |
| 37165762 | Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis. | J Diabetes | 2023 | https://conductscience.org/library/papers/37165762 | PubMed |
| 35986429 | DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. | Mil Med Res | 2022 | https://conductscience.org/library/papers/35986429 | PubMed |
| 35923194 | Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis. | Front Nutr | 2022 | https://conductscience.org/library/papers/35923194 | PubMed |
| 34888012 | Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review. | World J Diabetes | 2021 | https://conductscience.org/library/papers/34888012 | PubMed |
| 34679685 | Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34679685 | PubMed |
| 34489872 | Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34489872 | PubMed |
| 33570554 | DPP4 Activity, Hyperinsulinemia, and Atherosclerosis. | J Clin Endocrinol Metab | 2021 | https://conductscience.org/library/papers/33570554 | PubMed |
| 33397376 | Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. | Cardiovasc Diabetol | 2021 | https://conductscience.org/library/papers/33397376 | PubMed |
| 32900588 | Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? | J Diabetes Complications | 2020 | https://conductscience.org/library/papers/32900588 | PubMed |
| 32886301 | [18F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus. | Mol Imaging Biol | 2021 | https://conductscience.org/library/papers/32886301 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| DPP4 | 1803 | PubTator's text mining | https://conductscience.org/library/genes/1803 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28244635
GET https://conductscience.org/api/papers/v1/28244635/cited_by?page=2